Alphatec Holdings Q3 2026 results miss estimates and cuts full‑year revenue outlook

Alphatec Holdings reported third‑quarter 2026 revenue of $221 million, up 13% year‑over‑year, but below analyst expectations. Adjusted EBITDA was $38 million, a 17% margin, up 400 basis points YoY. The company lowered its full‑year 2026 revenue guidance to approximately $862 million, citing weaker biologics attachment and softer procedure mix. CEO Pat Miles said the firm will focus on improving biologics performance while surgical hardware growth remains strong.

The reduced revenue outlook narrows the growth target for investors and may pressure the stock, which has already fallen sharply. The company still expects adjusted EBITDA of about $137 million for the year, indicating continued margin expansion despite lower revenue.

Sources